Ampersand and 1315 Capital closes buy of Genoptix

Ampersand Capital Partners and 1315 Capital has completed its previously announced acquisition of Genoptix. The seller was Novartis. No financial terms were disclosed. Based in Carlsbad, California, Genoptix is a hematopathology center.

DealsNorth AmericaUSBriefs